QV Investors Inc. Has $17.16 Million Holdings in Solventum Corporation $SOLV

QV Investors Inc. raised its holdings in shares of Solventum Corporation (NYSE:SOLV) by 15.0% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 235,082 shares of the company’s stock after acquiring an additional 30,690 shares during the quarter. Solventum makes up 1.5% of QV Investors Inc.’s investment portfolio, making the stock its 26th largest holding. QV Investors Inc.’s holdings in Solventum were worth $17,161,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Nisa Investment Advisors LLC boosted its stake in shares of Solventum by 0.6% during the 2nd quarter. Nisa Investment Advisors LLC now owns 33,974 shares of the company’s stock valued at $2,577,000 after buying an additional 210 shares during the period. South Dakota Investment Council raised its holdings in shares of Solventum by 3.6% during the second quarter. South Dakota Investment Council now owns 255,625 shares of the company’s stock worth $19,387,000 after acquiring an additional 8,960 shares in the last quarter. Chelsea Counsel Co. boosted its position in Solventum by 720.7% during the second quarter. Chelsea Counsel Co. now owns 10,595 shares of the company’s stock valued at $804,000 after purchasing an additional 9,304 shares during the last quarter. Purus Wealth Management LLC purchased a new position in Solventum in the second quarter valued at about $252,000. Finally, ST Germain D J Co. Inc. increased its position in Solventum by 84.6% in the 2nd quarter. ST Germain D J Co. Inc. now owns 825 shares of the company’s stock worth $63,000 after purchasing an additional 378 shares during the last quarter.

Solventum Stock Performance

NYSE:SOLV opened at $80.28 on Friday. The firm has a market capitalization of $13.92 billion, a PE ratio of 9.25, a PEG ratio of 7.35 and a beta of 0.34. Solventum Corporation has a 1 year low of $60.70 and a 1 year high of $88.20. The company has a current ratio of 1.50, a quick ratio of 1.14 and a debt-to-equity ratio of 1.03. The firm’s fifty day simple moving average is $81.58 and its 200 day simple moving average is $75.69.

Solventum (NYSE:SOLV) last released its quarterly earnings results on Thursday, November 6th. The company reported $1.50 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.43 by $0.07. The company had revenue of $2.10 billion during the quarter, compared to analysts’ expectations of $2.05 billion. Solventum had a net margin of 18.13% and a return on equity of 28.01%. The business’s quarterly revenue was up .7% compared to the same quarter last year. During the same period in the prior year, the company earned $1.64 earnings per share. Solventum has set its FY 2025 guidance at 5.980-6.080 EPS. On average, sell-side analysts anticipate that Solventum Corporation will post 6.58 EPS for the current year.

Solventum declared that its Board of Directors has approved a share repurchase program on Thursday, November 20th that allows the company to buyback $1.00 billion in shares. This buyback authorization allows the company to repurchase up to 7.5% of its stock through open market purchases. Stock buyback programs are usually an indication that the company’s leadership believes its shares are undervalued.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on SOLV shares. Zacks Research lowered Solventum from a “strong-buy” rating to a “hold” rating in a report on Monday, December 1st. Stifel Nicolaus lifted their target price on shares of Solventum from $88.00 to $105.00 and gave the company a “buy” rating in a research note on Wednesday, January 7th. Mizuho set a $100.00 price target on shares of Solventum and gave the stock an “outperform” rating in a research note on Tuesday. UBS Group restated a “neutral” rating on shares of Solventum in a report on Friday, November 21st. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Solventum in a report on Thursday, October 30th. Six research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Solventum currently has a consensus rating of “Hold” and a consensus target price of $90.27.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.